ASSOCIATED PSEUDOMONOSIS AND RABBIT VIRAL HAEMORRHAGIC DISEASE VACCINE Russian patent published in 2014 - IPC A61K39/125 

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science and aims at the preventing pseudomonosis and rabbit viral haemorrhagic disease. As antigens, the vaccine contains a pure culture cell suspension of the pseudomonosis agent Pseudomonas aeruginosa and the rabbit viral haemorrhagic disease agent produced by sampling the involved organs of dead rabbits from a local epizootic centre. The suspension is prepared with the differential diagnostic media inoculated and pure agent cultures recovered. The growth procedure is performed separately in beef-extract broth of Pseudomonas aeruginosa with glucose in the concentration of microbial cells 4-5 bn in 1 cm³. The 10-15% rabbit liver suspension is prepared after being infected with the rabbit viral haemorrhagic disease, with an activity of not less than 10^3.0 LD50/cm³. This is mixed in equal ratios of formalin and aluminium hydroxide in the following proportions, wt %: pure culture cell suspension of the pseudomonosis agent Pseudomonas aeruginosa recovered from the local epizootic centre in the nutrient medium with a titre of 4-5 bn microbial cells in 1 cm³ 38.0-41.5, the rabbit liver suspension with the rabbit haemorrhagic disease virus recovered from the local epizootic centre in normal saline with an activity of not less than 10^3.0-4.0 LD₅₀/cm³ - 38.0-41.5, glucose - 2.0-1.0, formalin - 2.0-1.5, aluminium hydroxide - the rest.

EFFECT: using the declared invention enables higher specificity and efficacy of the associated pseudomonosis and rabbit viral haemorrhagic disease with no negative side effect on the animals.

1 tbl, 5 ex